Key result
Long-term growth hormone therapy leaves suPAR levels unchanged despite lowering CRP in adult deficiency.
Why the study?
Growth hormone deficiency is associated with cardiovascular disease risk factors including metabolic inflammation, but the impact of growth hormone deficiency and treatment on low-grade inflammation is unknown.
Does long-term growth hormone replacement therapy influence serum levels of the low-grade inflammation biomarkers suPAR and hsCRP in adults with growth hormone deficiency?
Cohort (n=72)
No
Does long-term growth hormone replacement therapy influence serum levels of the low-grade inflammation biomarkers suPAR and hsCRP in adults with growth hormone deficiency?
Answers are grounded in this paper and cite their sources.
In adults with growth hormone deficiency receiving long-term GH replacement over a mean of 8 years, serum suPAR levels remained stable without an expected age-related increase while CRP levels significantly decreased, suggesting a favorable effect of GH therapy on low-grade inflammation.
Growth hormone deficiency (GHD) syndrome is associated with adverse levels of several risk factors for cardiovascular diseases (CVD), including metabolic inflammation. However, the impact of GHD and GH treatment on low-grade inflammation is unknown. The aim of the study was to establish the level of the low-grade inflammation biomarker soluble urokinase plasminogen activator receptor (suPAR) in adults with GHD and the response to long-term GH treatment. Measurements of suPAR and CRP were performed in bio-bank serum samples from 72 adults, 34 males and 38 females, with GHD before and during at least 5 years of GH treatment. Mean age was 52.5 ± 15.5 years, BMI 27.3 ± 5 kg/m2. Clinical evaluations and blood sampling were performed at routine visits. Data on demography, anthropometry, lab results and clinical events were retrieved from post-marketing surveillance study databases and medical records. suPAR and high-sensitive (hs) CRP were analysed using ELISA and immunochemistry, respectively. At baseline blood pressure, lipid profile and fasting glucose were within the normal reference range. Baseline geometric mean and 95% CI of suPAR was 2.9 (2.7-3.3) ng/mL and of CRP 2.3 (0.6-4.0) mg/L. Mean follow-up was 8 ± 2 years. The suPAR levels remained stable during follow-up, although individual increases were seen on occurrence or presence of co-morbidities. In contrast, levels of CRP decreased. In conclusion, the decrease in CRP and indirectly the absence of an expected increase in suPAR over time indicates a favourable effect of GH on low-grade inflammation.
No takes yet. Share an insight, caveat, or question.
Höybye et al. (2019) conducted a cohort in Growth hormone deficiency (GHD) in adults (n=72). Long-term growth hormone (GH) treatment was evaluated on Baseline and longitudinal serum soluble urokinase plasminogen activator receptor (suPAR) levels during long-term GH treatment (95% CI 2.7-3.3, p=0.36). Long-term growth hormone treatment in 72 adults with growth hormone deficiency resulted in stable suPAR levels and decreased CRP levels.
Synapse has enriched 10 related papers. Consider them for comparative context: